Non-alcoholic fatty liver disease (NAFLD) is considered to be among the most common liver diseases world-wide. NAFLD encompasses a broad spectrum of pathological conditions ranging from Simple Steatosis (SS) to steatohepatitis (NASH), fibrosis and finally even cirrhosis. Adiponectin (A) has been associated with inhibition of fibrogenesis and liver protection while Leptin (L) contributes to fibrogenesis in various chronic liver diseases, notably in NASH. The aim of work: To determine the validity of serum adipokines including leptin, adiponectin, and A/L ratio to act as potential markers for NAFLD and to discriminate NASH from SS. Patients and methods: Eighty four patients who have bright liver on abdominal ultrasonography and 28 healthy individuals served as control group.
Amin MA, Ashmawi K, Shakr O, Mussa S, Samie RMA, et al. (2015) Serum Adipokines in Patients with Non-alcoholic Fatty Liver Disease - Is there a Role for Predicting the Severity of Liver Disease? Intern Med 4:191. doi: 10.4172/2165-8048.1000191